Biotech news for Friday, July 24, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Arrowhead Pharmaceuticals (ARWR) surged over 20% to a new 52-week high after reporting positive late-stage trial results for its lipid-lowering agent. Cantor Fitzgerald called the win a 'meaningful derisking event,' boosting investor confidence in the drug's r…
The FDA accepted Revolution Medicines' New Drug Application for daraxonrasib as a second-line treatment for metastatic pancreatic ductal adenocarcinoma. The submission is backed by the Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in the risk…
BridgeBio Pharma announced FDA acceptance of its New Drug Application for encaleret, a treatment for autosomal dominant hypocalcemia type 1, a rare form of hypoparathyroidism. The FDA granted a target review date, moving the therapy closer to potential approva…
Arrowhead Pharmaceuticals announced positive late-stage trial results for plozasiran in severe hypertriglyceridemia, a direct competitor to Ionis's marketed therapy. The news sent Ionis shares down, highlighting the competitive threat to its lipid-lowering dru…
Summit Therapeutics (SMMT) released updated overall survival data from a Phase 3 trial of ivonescimab, a lung cancer drug developed with Akeso (AKESF). Shares dipped ~1% premarket on the news. The data is critical for investors as it may influence the drug's r…
Dyne Therapeutics (DYN) announced an upsized public offering of 18.3 million shares at $20.50 each, raising approximately $375 million. The stock slipped on the news, reflecting dilution concerns for investors.
Liquidia (LQDA) shares jumped 8% after a judge criticized United Therapeutics (UTHR) lawyers in a patent dispute filing. United Therapeutics fell 1.2%. The judge's remarks could signal a favorable outcome for Liquidia, potentially clearing the path for its dru…
Dyne Therapeutics (DYN) announced a $300M public stock offering at a discount of up to 16%, causing shares to fall 14% in after-hours trading. The offering dilutes existing shareholders, raising concerns about near-term stock performance.
Tiziana Life Sciences (TLSA) executive chairman Gabriele Cerrone bought 42,357 common shares at $0.99 each, raising his total holdings to 44.81M shares and his beneficial ownership to 34.93%. Insider buying signals confidence in the company's prospects, includ…
The FDA has dissolved and will reconstitute its Peripheral and Central Nervous System Drugs Advisory Committee, as per a Federal Register notice. This panel reviews drugs for conditions like Alzheimer's and pain, impacting companies such as Eli Lilly (LLY) and…
Celldex (CLDX) fell ~6% after-hours Tuesday as its drug barzolvolimab missed primary and secondary endpoints in a phase 2 trial for prurigo nodularis. The failure to achieve a meaningful improvement in WI-NRS scores raises concerns about the drug's efficacy in…
Agios Pharmaceuticals (AGIO) is discontinuing development of tebapivat for sickle cell disease after a Phase 2 trial failed to show sufficient efficacy versus placebo. The stock fell up to 11% on the news, highlighting the setback for the company's pipeline.